Clinical trial · Observational
Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review
Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia With and Without FLT3 Mutation
NCT03047083CI-TRIAL-00082231completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to retrospectively evaluate the treatment patterns and AML-related key healthcare resource use among AML patients, stratified by FLT3 mutation status, intensive chemotherapy (IC) eligibility, and relapsed or refractory (R/R) status.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AML-related healthcare resources | Other | — | UNRESOLVED |
| Treatment patterns among AML patients | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (6)
- label
- IC eligible AML patients with FLT3 mutation
- description
- Newly diagnosed AML patients
- interventionNames
- Other: Treatment patterns among AML patients
- Other: AML-related healthcare resources
- label
- IC ineligible patients with FLT3 mutation
- description
- Newly diagnosed AML patients
- interventionNames
- Other: Treatment patterns among AML patients
- Other: AML-related healthcare resources
- label
- AML patients after R/R with FLT3 mutation
- description
- R/R are relapse/refractory patients
- interventionNames
- Other: Treatment patterns among AML patients
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Confirmed diagnosis of AML but NOT acute promyelocytic leukemia (APL) * Known FLT3 mutation status * Under the care of the participating physician during the past 3 years OR from the initial diagnosis of AML * The medical records related to AML for the patient are available to the physician and can be abstracted for this study * The medical records contains complete information on treatments and AML-related hospitalization, including admission date, length of stay, and reason of hospitalization * Initiation date of first treatment after AML diagnosis OR date of being classified as relapsed from or being refractory to initial treatment (R/R) is between January 1, 2013 and December 31, 2015 Exclusion Criteria: * Not applicable
References
Publications (0)
Data not yet available
No reference posted for this study.